Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I, First-in-Human Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of (ML-246) in Patients With Metastatic Solid Tumors, including Pancreatic Cancer

The purpose of this phase I trial is to find a safe dose of metarrestin and to see if this dose shrinks tumors.

NCT#: NCT04222413
Study ID: 200023
Trial Phase: Phase I

Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Metarrestin

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Back to Trial Search